Gene therapy has been a priority for Greffex's research team, since its key obstacle, immune interference, can be controlled by Greffex’s vectors.

Initial forays into gene therapy in the 1990s met with failure for several reasons. Attempts at manipulating genes using retroviral vectors resulted in a much higher incidence of cancer in trial participants, and one patient's fatal immune reaction to an early-generation adenoviral vector convinced many that the solution to gene therapy did not lie with viral vectors. However, Greffex's proprietary FDHI vector has been stripped of its immunoreactive properties and further protected by our Engineered Veto© technology, making it the solution to the question of vector-based gene therapy.

Our FDHI virus is especially suited to gene therapy, as it can carry large DNA payloads. One such payload is the Factor VIII gene, the deficiency of which is associated with hemophiliacs' inability to form blood clots. Although the Factor VIII gene is considered large, our FDHI virus is able carry payloads much larger than the Factor VIII gene. Currently, Greffex possesses a GMP facility able to produce FDHI vectors stuffed with both the Factor VIII gene and the anti-rejection Engineered Veto© molecule.